{{Infobox symptom
 | Name           = 微量白蛋白尿<br>(Microalbuminuria)
 | Image          =
 | Caption        =
 | Field          = [[腎臟科|腎臟科]]
 | DiseasesDB     =
 | ICD10          =
 | ICD9           = {{ICD9|791.0}}
 | ICDO           =
 | OMIM           =
 | MedlinePlus    = 003591
 | eMedicineSubj  =
 | eMedicineTopic =
 | MeshID         = 
}}

'''微量白蛋白尿'''(microalbuminuria)是用來描述白蛋白尿水平適度增加的醫學術語。它發生在[[腎|腎]]洩漏少量[[人血清白蛋白|白蛋白]](Human serum albumin)進入尿液裡、換言之，即在腎臟[[腎小球|腎小球]]的白蛋白有異常高的[[血管通透性|滲透性]](Vascular permeability)。這個醫學術語"微量白蛋白尿"現在KDIGO(Kidney Disease Improving Global Outcomes/腎臟病改善全球成果)計劃不建議使用，並以"中度增加[[白蛋白尿|白蛋白尿]]"取代之。

==病因==
*血管[[內皮功能障礙|內皮功能障礙]](endothelial dysfunction)的標誌。
*腎臟疾病預後的重要標誌：
<!--** in [[diabetes_mellitus|diabetes mellitus]]
** in [[hypertension|hypertension]]
** in [[post-streptococcal_glomerulonephritis|post-streptococcal glomerulonephritis]]
* increasing microalbuminuria during the first 48 hours after admission to an [[intensive_care_unit|intensive care unit]] predicts elevated risk for acute [[respiratory_failure|respiratory failure]], [[multiple_organ_failure|multiple organ failure]], and overall mortality
* a risk factor for venous thromboembolism<ref>{{cite journal|pmid=19417196|year=2009|last1=Mahmoodi|first1=BK|last2=Gansevoort|first2=RT|last3=Veeger|first3=NJ|last4=Matthews|first4=AG|last5=Navis|first5=G|last6=Hillege|first6=HL|last7=Van Der Meer|first7=J|author8=Prevention of Renal Vascular End-stage Disease (PREVEND) Study Group|title=Microalbuminuria and risk of venous thromboembolism|volume=301|issue=17|pages=1790–7|doi=10.1001/jama.2009.565|journal=JAMA: the Journal of the American Medical Association}}</ref>

Microalbuminuria is an important adverse predictor of glycemic outcomes in pre-diabetes. Pre-diabetes individuals with increased microalbuminuria even in the so-called normal range is associated with increased progression to diabetes and decreased reversal to normoglycemia. Hence prediabetes individuals with microalbuminuria warrant more aggressive intervention to prevent diabetes in them.<ref>Dutta D, Choudhuri S, Mondal SA, Mukherjee S, Chowdhury S. Urine albumin creatinine rationpredicts prediabetes progression to diabetes and reversal to normoglycemia: Role of associatedinsulin resistance, inflammatory cytokines and low vitamin-D. J Diabetes 2014 Jul;6(4):316-22 PMID 24251376 http://www.ncbi.nlm.nih.gov/pubmed/24251376</ref>-->

==診斷==
<!--The level of albumin [[protein|protein]] produced by microalbuminuria can be detected by special albumin-specific urine [[dipstick|dipstick]]s. A [[microalbumin_urine_test|microalbumin urine test]] determines the presence of the albumin in urine. In a properly functioning body, albumin is not normally present in urine because it is retained in the bloodstream by the kidneys.-->

<!--Microalbuminuria can be diagnosed from a 24-hour urine collection (between 30–300 mg/24 hours) or, more commonly, from elevated concentrations in a spot sample (30 to 300 mg/L).  Both must be measured on at least two of three measurements over a two- to three-month period.<ref>{{cite web |url=http://meteor.aihw.gov.au/content/index.phtml/itemId/270336 |title=Person—microalbumin level (measured), total micrograms per minute N[NNN].N |accessdate=2007-07-05 |work=}}</ref>-->

<!--An albumin level above the upper limit values is called "macroalbuminuria", or sometimes just [[albuminuria|albuminuria]]. Sometimes, the upper limit value is given as one less (such as 300 being given as 299) to mark that the higher value (here 300) is defined as macroalbuminuria.<ref name=Lee2009/>-->

<!--To compensate for variations in urine concentration in spot-check samples, it is helpful to compare the amount of albumin in the sample against its concentration of [[creatinine|creatinine]]. This is termed the '''albumin/creatinine ratio''' ('''ACR''')<ref>{{cite journal | pmid = 10333950 | volume=22 | issue=2 | title=Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration |date=February 1999 | author=Bakker AJ | journal=Diabetes Care | pages=307–13 | doi=10.2337/diacare.22.2.307}}</ref> and microalbuminuria is defined as ACR ≥3.5 mg/mmol (female) or ≥2.5 mg/mmol (male),<ref>{{cite web |title=Proteinuria |date=December 15, 2005 |url=http://www.renal.org/eGFR/proteinuria.html |publisher=UK Renal Association |access-date=2015-06-25 |archive-url=https://web.archive.org/web/20070814104930/http://www.renal.org/eGFR/proteinuria.html |archive-date=2007-08-14 |dead-url=yes }}</ref> or, with both substances measured by mass, as an ACR between 30 and 300 µg albumin/mg creatinine.<ref>[http://www.clinlabnavigator.com/index.php?option=com_content&view=article&id=412:microalbumin&catid=35:test-interpretations clinlabnavigator.com > Test Interpretations] Last Updated on Saturday, 19 June 2010</ref>
For the diagnosis of microalbuminuria, care must be taken when collecting sample for the urine ACR. An early morning sample is preferred. The patient should refrain from heavy exercises 24 hours before the test. A repeat test should be done 3 to 6 months after the first positive test for microalbuminuria. Lastly, the test is inaccurate in a person with too much or too little muscle mass. This is due to the variation in creatinine level which is produced by the muscle.<ref>[http://www.treatmentandsymptoms.com/renal-nephrology/microalbuminuria-in-type-2-diabetes-mellitus/ Microalbuminura in diabetes]</ref>-->

{|class="wikitable" align="center"
|+ 微量白蛋白尿定義
|-
!  !! 個人 !! 底限 !! 高限 !! 單位
|-
! 24小時尿液收集
|  || 30<ref name=Lee2009>[http://books.google.com/books?id=AUSIRcV_as0C&pg=PA291 Page 90] in: {{Citebook|title=Basic Skills in Interpreting Laboratory Data|isbn=978-1-58528-180-0}}</ref> || 300<ref name=Lee2009/> || mg/24h (每24小時的[[毫克|毫克]]白蛋白)
|-
! 短時間尿液收集
|  || 20<ref name=Lee2009/> || 200<ref name=Lee2009/> || µg/min (每分鐘的[[微克|微克]]白蛋白)
|-
! 定點白蛋白尿樣本
|  || 30<ref name=aihw>[http://meteor.aihw.gov.au/content/index.phtml/itemId/270339 Person—microalbumin level (measured)] {{Wayback|url=http://meteor.aihw.gov.au/content/index.phtml/itemId/270339 |date=20210827210915 }} at Australian Institute of Health and Welfare. 01/03/2005</ref> || 300<ref name=aihw/> || mg/L (每[[公升|公升]]尿液的毫克白蛋白)
|-
!rowspan=4| 定點白蛋白尿/肌酸酐比值
|rowspan=2| 女人 || 3.5<ref name=Justesen2006>[http://care.diabetesjournals.org/content/29/4/924.full] {{Wayback|url=http://care.diabetesjournals.org/content/29/4/924.full |date=20210827210914 }} {{cite journal|title=Albumin-to-creatinine ratio in random urine samples might replace 24-h urine collections in screening for micro- and macroalbuminuria in pregnant woman with type 1 diabetes|pages=924–925|issn=0149-5992|journal=Diabetes Care|volume=29|issue=4|date=2006-4|url=https://www.ncbi.nlm.nih.gov/pubmed/16567839|accessdate=2019-02-13|author=Thomas I. Justesen, Jens L. A. Petersen, Pia Ekbom, Peter Damm, Elisabeth R. Mathiesen|pmid=16567839|archive-date=2019-08-22|archive-url=https://web.archive.org/web/20190822084859/https://www.ncbi.nlm.nih.gov/pubmed/16567839|dead-url=no}}</ref> || 25<ref name=Justesen2006/> or 35<ref name=Justesen2006/> || mg/mmol (每[[摩尔_(单位)|摩爾]]肌酸酐的毫克白蛋白) 
|-
| 30<ref name=Justesen2006/> || 400<ref name=Justesen2006/> || μg/mg (每毫克肌酸酐的毫克白蛋白)
|-
|rowspan=2| 男人 || 2.5<ref name=Justesen2006/> or 3.5<ref name=Justesen2006/> || 25<ref name=Justesen2006/> or 35<ref name=Justesen2006/> || mg/mmol 
|-
| 30<ref name=Justesen2006/> || 300<ref name=Justesen2006/> || μg/mg
|}

==參見==
* [[白蛋白尿|白蛋白尿]]

==註釋==
{{reflist}}

==參考文獻==
{{refbegin|2}}
* {{cite journal |author=Abid O, Sun Q, Sugimoto K, Mercan D, {{link-en|Vincent JL|Jean-Louis Vincent}} |title=Predictive value of microalbuminuria in medical ICU patients: results of a pilot study |url=https://archive.org/details/sim_chest_2001-12_120_6/page/1984 |journal=Chest |volume=120 |issue=6 |pages=1984–8 |year=2001 |pmid=11742932 |doi=10.1378/chest.120.6.1984}}
* {{cite journal |author=Andersen S, Blouch K, Bialek J, Deckert M, Parving HH, Myers BD |title=Glomerular permselectivity in early stages of overt diabetic nephropathy |url=https://archive.org/details/sim_kidney-international_2000-11_58_5/page/2129 |journal=Kidney Int. |volume=58 |issue=5 |pages=2129–37 |year=2000 |pmid=11044234 |doi=10.1111/j.1523-1755.2000.00386.x}}
* {{cite journal |author=Heart Outcomes Prevention Evaluation Study Investigators  |title=Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy |journal=Lancet |volume=355 |issue=9200 |pages=253–9 |year=2000 |pmid=10675071 |doi=10.1016/S0140-6736(99)12323-7}}
* {{cite journal |author=Lemley KV |title=Evolution of incipient nephropathy in type 2 diabetes mellitus |url=https://archive.org/details/sim_kidney-international_2000-09_58_3/page/1228 |journal=Kidney Int. |volume=58 |issue=3 |pages=1228–37 |year=2000 |pmid=10972685 |doi=10.1046/j.1523-1755.2000.00223.x |author2=Abdullah I |author3=Myers BD |display-authors=3 |last4=Meyer |first4=Timothy W |last5=Blouch |first5=Kristina |last6=Smith |first6=William E |last7=Bennett |first7=Peter H |last8=Nelson |first8=Robert G}}
* {{cite journal |author=Lièvre M |title=The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group |journal={{le|受控臨床試驗|Controlled Clinical Trials|Controlled Clinical Trials}} |volume=21 |issue=4 |pages=383–96 |year=2000 |pmid=10913814 |doi=10.1016/S0197-2456(00)00060-X |author2=Marre M |author3=Chatellier G |display-authors=3 |last4=Plouin |first4=P |last5=Réglier |first5=J |last6=Richardson |first6=L |last7=Bugnard |first7=F |last8=Vasmant |first8=D}}
* {{cite journal |author=Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P |title=The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes |journal=N. Engl. J. Med. |volume=345 |issue=12 |pages=870–8 |year=2001 |pmid=11565519 |doi=10.1056/NEJMoa011489}}
* Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter., Suppl. 2013; 3: 1-150.
{{refend}}

==外部連結==
* [http://labtestsonline.org/understanding/analytes/microalbumin/tab/test Microalbumin and Urine Albumin/Creatinine Ratio] {{Wayback|url=http://labtestsonline.org/understanding/analytes/microalbumin/tab/test |date=20170728020722 }} – Lab Tests Online
* [http://www.pace-med-apps.com/uAlbCalc.htm Online Microalbumin Urine Calculator] {{Wayback|url=http://www.pace-med-apps.com/uAlbCalc.htm |date=20160308112338 }}

{{Abnormal clinical and laboratory findings for urine}}

[[Category:尿液臨床與實驗室異常所見|Category:尿液臨床與實驗室異常所見]]